Related Experiment Video
Updated: Feb 13, 2026
10:08
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
Published on: February 17, 2018
14.0K
Stem Cell Therapy in Patients with Chronic Nonischemic Heart Failure
Gregor Poglajen1, Gregor Zemljič1, Sabina Frljak1
1Advanced Heart Failure and Transplantation Center, University Medical Center Ljubljana, Ljubljana, Slovenia.
Stem Cells International
|March 15, 2018
Summary
Stem cell therapy shows promise for dilated cardiomyopathy (DCMP), improving heart function. Personalized approaches using optimal cell types, doses, and delivery methods are key for future treatments.
Area of Science:
- Cardiology
- Regenerative Medicine
- Cell Therapy
Background:
- Chronic non-ischemic heart failure, specifically dilated cardiomyopathy (DCMP), presents a significant clinical challenge.
- Current therapeutic strategies for DCMP have limitations, necessitating novel treatment approaches.
Purpose of the Study:
- To review recent advancements in the clinical application of stem cell therapy for DCMP.
- To focus on critical aspects including patient selection, types of stem cells used, and delivery techniques.
Main Methods:
- Review of current literature on stem cell therapy in DCMP.
- Analysis of studies investigating various stem cell types and their efficacy.
- Evaluation of delivery methods and patient stratification strategies.
Main Results:
- Bone marrow-derived cells and CD34+ cells have shown improvements in myocardial performance and functional capacity.
- Allogeneic mesenchymal stem cells demonstrate effectiveness in enhancing heart function in DCMP patients.
- Stem cell therapy appears more promising for DCMP than for chronic ischemic heart failure, where results have been inconsistent.
Conclusions:
- Stem cell therapy offers a promising avenue for treating DCMP, with encouraging clinical trial outcomes.
- Further research should focus on personalized stem cell strategies, optimizing cell type, dose, and delivery for individual patients.
- Developing standardized stem cell products is crucial for widespread clinical adoption in DCMP management.
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
395
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
395
01:29Heart Failure II: Pathophysiology
1.0K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
01:17Pathophysiology of Heart Failure
4.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
01:27Heart Failure I: Introduction
951
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
951
01:22Heart Failure Drugs: Diuretics
1.0K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K
01:30Heart Failure V: Medical Management
360
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
360